BriaCell Therapeutics Price, Forecast, Insider, Ratings, Fundamentals & Signals

Philadelphia and vancouver, british columbia, april 10, 2024 (globe newswire) -- briacell therapeutics corp. (nasdaq: bctx, bctxw) (tsx: bct) (“briacell” or the “company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today is pleased to report preclinical data showing strong anti-cancer activity of its next generation, personalized, off-the-shelf, cell-based breast and prostate cancer immunotherapies, bria-ots+™ and bria-pros+™, in a poster session during the 2024 american association for cancer research (aacr) annual meeting held from april 5-10 at san diego convention center, san diego, ca.

Philadelphia and vancouver, british columbia, march 07, 2024 (globe newswire) --  briacell therapeutics corp. (nasdaq: bctx, bctxw) (tsx: bct) (“briacell” or the “company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces that it has received and executed a letter of intent with paula pohlmann, md, msc, phd, associate professor, department of investigational cancer therapeutics and breast medical oncology, division of cancer medicine, the university of texas md anderson cancer center, houston, tx to advance the clinical development of bria-ots+ and bria-pros+, briacell's personalized off-the-shelf cellular cancer vaccines in advanced breast cancer and prostate cancer, respectively.

Philadelphia and vancouver, british columbia, march 06, 2024 (globe newswire) -- briacell therapeutics corp. (nasdaq: bctx, bctxw) (tsx: bct) (“briacell” or the “company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce that the company will be presenting three posters at the 2024 american association for cancer research (aacr) annual meeting taking place april 5-10 at san diego convention center, san diego, ca. the details are listed below.

Philadelphia and vancouver, british columbia, feb. 27, 2024 (globe newswire) -- briacell therapeutics corp. (nasdaq: bctx, bctxw) (tsx: bct) (“briacell” or the “company”), a clinical-stage biotechnology  company that develops novel immunotherapies to transform cancer care, provides an update to the  previously announced investigation  of alleged illegal trading activity of its publicly traded securities.

Philadelphia and vancouver, british columbia, feb. 07, 2024 (globe newswire) -- briacell therapeutics corp. (nasdaq: bctx, bctxw) (tsx: bct) (“briacell” or the “company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to report preliminary disease control rate of 61% in evaluable (i.e. exhibited clinical outcomes) phase 2 advanced breast cancer patients treated with briacell's bria-imt™ regimen – the same formulation being used in briacell's open pivotal phase 3 study. additionally, a disease control rate of 50% was reported in similarly treated evaluable patients who had failed prior antibody-drug conjugate (adc) therapy.

BriaCell Therapeutics aims to create cancer immunotherapy by irradiating and engineering existing cancer cells. Lead candidate Bria-IMT for breast cancer showed good tolerability and efficacy in 46 heavily pretreated patients so far.

PHILADELPHIA and VANCOUVER, British Columbia, Sept. 28, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, is pleased to announce that its lead product candidate, Bria-IMT™, will be featured in three posters during the 2022 San Antonio Breast Cancer Symposium® taking place December 6-10, 2022 at the Henry B. Gonzalez Convention Center in San Antonio, Texas.

BriaCell Therapeutics (BCTX) stock is on the move Wednesday morning after getting Fast Track approval from the FDA for Bria-IMT. The post Why Is BriaCell (BCTX) Stock Moving Today?

BriaCell Therapeutics Corp (NASDAQ: BCTX) shares are trading higher Wednesday after the company announced the U.S. Food and Drug Administration granted Fast Track status to Bria-IMT for the treatment of metastatic breast cancer. Bria-IMT is a cell-based immunotherapy.

The shares of Briacell Therapeutics Corp (NASDAQ:BTCX) are up 6.8% at $8.53 this morning, following the company's announcement that an insider intends to acquire up to 1.59 million shares, which represents 10% of its public market securities.

Fintel's list of short squeeze stocks to watch for this week is in. Here are the names that investors should be watching.

Photo by Artem Podrez from Pexels Too many companies and small businesses to count were buried under the avalanche of a global pandemic in the past 18 months. And as horrible as it was to lose your favorite restaurant or dry cleaner, imagine the impact of losing a company that had devoted itself to enhancing the lives of women with breast cancer.

BriaCell Therapeutics Corp (NASDAQ: BCTX) has announced a multi-year, non-exclusive license agreement with ImaginAb Inc for developing next-generation immuno-oncology imaging agents and radiopharmaceutical therapies. Under the agreement terms, ImaginAb will supply clinical doses of its CD8 ImmunoPET technology (89Zr-Df-Crefmirlimab) to BriaCell for use in BriaCell's ongoing Phase 1/2a study with Incyte Corporation (NASDAQ: INCY) in metastatic or locally recurrent breast cancer patients.

Photo by Chokniti Khongchum from Pexels In 2020, there were 2.3 million women globally diagnosed with breast cancer and 685,000 deaths, according to the World Health Organization. In the U.S., 12.9% of women born in the country today will develop breast cancer at some time during their lifetime.

BriaCell Therapeutics Corp (NASDAQ: BCTX) has opened recruitment and enrollment of their collaborative clinical study with Incyte Corporation (NASDAQ: INCY).  The Phase 1/2a combination study will evaluate BriaCell's lead candidate, Bria-IMT, with Incyte's retifanlimab & epacadostat to treat advanced breast cancer.